TCR² Therapeutics Leadership

Dr. Justice joined TCR² in 2019 as Chief People Officer. She offers nearly 20 years of experience in healthcare, medical affairs and human resources leadership. Prior to joining, she was Executive Vice President and Chief Human Resources Officer at Surgery Partners, playing a critical role in leading talent management strategy and launching a multi-year rewards strategy to incentivize organic growth. Before that, Dr. Justice worked at Biogen as the Chief Learning Officer where she assumed a variety of responsibilities including creating and leading a centralized learning organization supporting 14,000 people across all departments and geographies, spearheading the implementation of a learning technology system, and making learning a competitive force with measurable business impact. Earlier at Biogen, Angela served as Senior Director of Global Medical Affair and was an active member of the Human Resources Leadership Team. Previously, she held leadership roles at EMD Serono, the National MS Society and was a management consultant at McKinsey & Company. Dr. Justice received her Ph.D. in Biopsychology from the University of Chicago.

Rosemary Harrison is the Chief Business and Strategy Officer at TCR² Therapeutics Inc. Rosemary Harrison attended The University of Queensland.

Mr. Olagunju joined TCR² in 2021 as Chief Technical Officer. He offers over 20 years of experience in cell and gene therapy, clinical development, program management, manufacturing and technical operations. Prior to joining the Company, he was Senior Vice President of Technical Operations at FerGene Inc., where he led the technical operations function for the commercialization of a gene therapy for bladder cancer. Before that, Mr. Olagunju was Vice President of Global Patient Operations at bluebird bio, Inc., where he held several roles of increasing responsibility and was the program lead and functional head of manufacturing supporting the European approval for ZYNTEGLO®, a transformational gene therapy for Transfusion dependent Thalassemia. Earlier in his career, he held senior positions in Commercial Technical Operations and served as the Head of Quality at Dendreon Corp. and ZymoGenetics, Inc. Mr. Olagunju holds an M.B.A. from the University of Washington and a B.S. in Biology from the University of Illinois at Urbana-Champaign.

Dr. Quintás-Cardama joined TCR² in 2017 as Chief Medical Officer. He offers nearly two decades of experience leading clinical strategy and regulatory filings for multiple oncology therapeutics resulting in market approval. Dr. Quintás-Cardama was the clinical development head of the Cell & Gene Therapies Unit at GlaxoSmithKline where he was responsible for the full clinical development strategy, execution and collaboration with Adaptimmune on affinity enhanced T-cell therapies. Previously, he served as Global Clinical Leader of Novartis’ now approved Kymriah™ (tisagenlecleucel) CTL019 program and was an Assistant Professor in the Department of Leukemia at MD Anderson Cancer Center. Dr. Quintás-Cardama earned his MD from the Universidad de Santiago de Compostela School of Medicine in Spain. He completed an internship and residency in the Department of Medicine, Albert Einstein College of Medicine in New York and a Hematology and Oncology fellowship at The University of Texas, MD Anderson Cancer Center.

Dr. Justice joined TCR² in 2019 as Chief People Officer. She offers nearly 20 years of experience in healthcare, medical affairs and human resources leadership. Prior to joining, she was Executive Vice President and Chief Human Resources Officer at Surgery Partners, playing a critical role in leading talent management strategy and launching a multi-year rewards strategy to incentivize organic growth. Before that, Dr. Justice worked at Biogen as the Chief Learning Officer where she assumed a variety of responsibilities including creating and leading a centralized learning organization supporting 14,000 people across all departments and geographies, spearheading the implementation of a learning technology system, and making learning a competitive force with measurable business impact. Earlier at Biogen, Angela served as Senior Director of Global Medical Affair and was an active member of the Human Resources Leadership Team. Previously, she held leadership roles at EMD Serono, the National MS Society and was a management consultant at McKinsey & Company. Dr. Justice received her Ph.D. in Biopsychology from the University of Chicago.